XSHE
300318
Market cap531mUSD
Jul 10, Last price
4.55CNY
1D
3.17%
1Q
-23.14%
Jan 2017
-49.78%
IPO
60.42%
Name
Beijing Bohui Innovation Biotechnology Group Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Bohui Innovation Biotechnology Group Co., Ltd. is a Chinese enterprise that manages the full spectrum of diagnostic product operations, from initial research and development through manufacturing, sales, and post-sale support. Their offerings include a variety of diagnostic tools such as the GenPlex microfluidic automated system for nucleic acid detection, immunofluorescence detection solutions, and products for analyzing human trace elements. Additionally, the company provides advanced chemical analysis instrumentation, featuring atomic fluorescence spectrometers, photometers, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, and ICP spectroscopy equipment, along with vital consumables for life sciences. Founded in 2001, the company is headquartered in Beijing, China. It adopted its current name, Beijing Bohui Innovation Biotechnology Group Co., Ltd., in August 2021, having previously been known as Beijing Bohui Innovation Biotechnology Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||